Hims & Hers Health (NYSE: HIMS) jumped sharply in Wednesday trading, with the stock climbing nearly 11% to $26.19 today after a landmark partnership with Novo Nordisk removed a key legal risk that had weighed on the company for months. The rally followed a bullish analyst update from Barclays, which lifted its price target on HIMS to $29 from $25 while maintaining an Overweight rating.
The market reaction highlights a turning point for the fast-growing telehealth company. For much of the past year, regulatory uncertainty surrounding compounded GLP-1 medications had overshadowed Hims & Hers’ strong revenue growth. The new agreement with Novo Nordisk appears to resolve that overhang and shifts the investment narrative back toward growth opportunities in the weight-loss drug market.
During the latest trading session reflected in the move, HIMS traded around $26.19, gaining $2.72 on the day. The stock moved between $22.82 and $26.08 intraday while volume reached about 24.19 million shares. The company’s market capitalization was roughly $5.95 billion.
Novo Nordisk agreement removes major legal overhang
The catalyst for the rally is a new distribution partnership between Hims & Hers and pharmaceutical giant Novo Nordisk. Under the agreement, Hims will distribute approved Novo Nordisk medications including Ozempic, Wegovy injectables, and the upcoming oral Wegovy pill through its telehealth platform at Novo’s official self-pay pricing.
The deal also resolves a legal dispute that began earlier this year. Novo Nordisk had filed a lawsuit in February after Hims introduced and then removed a compounded version of the Wegovy pill. As part of the resolution, Hims agreed to stop advertising compounded GLP-1 drugs except in clinically necessary cases.
The resolution was publicly supported by regulators, with the FDA describing the outcome as beneficial for patient access and affordability. The regulatory framework surrounding GLP-1 treatments continues to evolve, and oversight from agencies such as the U.S. Food and Drug Administration remains central to the market’s development.
Barclays analyst Glen Santangelo said the agreement acts as a dual catalyst for the stock. Beyond eliminating legal uncertainty, the firm believes investors may still be underestimating the product opportunity created by Hims’ access to Novo Nordisk’s approved weight-loss therapies.
Revenue growth and subscriber expansion remain strong
Operational performance has been one of the most compelling parts of the Hims story. The company reported $2.347 billion in full-year 2025 revenue, representing a striking 59% year-over-year increase. Fourth-quarter revenue reached $617.82 million, beating analyst expectations.
The company’s subscriber base also continued expanding, surpassing 2.5 million users, a gain of 13% year over year. Average monthly revenue per subscriber climbed to $83, reflecting both improved product adoption and increased monetization.
International expansion is another emerging growth driver. Revenue from markets outside the United States surged by roughly 825% year over year in the fourth quarter, though from a smaller base.
Wall Street sees potential for further re-rating
Barclays’ new $29 price target suggests the bank believes the stock still has room to run despite the recent rally. The broader analyst community is more cautious, with a consensus target near $23.12, meaning Barclays is notably more optimistic than many of its peers.
The company’s own outlook supports the growth narrative. Hims expects 2026 revenue between $2.7 billion and $2.9 billion and adjusted EBITDA in the range of $300 million to $375 million. Those projections indicate continued expansion as the telehealth platform scales its pharmacy and prescription offerings.
Capital investment is rising alongside that growth. Full-year capital expenditures reached $242.59 million, reflecting heavy spending on pharmacy automation and infrastructure.
Investor focus shifts from legal risk to growth potential
Despite the positive momentum, analysts still highlight several financial considerations. Hims carries roughly $1 billion in convertible debt, and the company reported negative free cash flow in the fourth quarter as capital spending increased.
The stock has also experienced significant volatility over the past year. Shares were down about 27.72% year-to-date and 31.91% over the past twelve months before the Novo deal triggered a sharp reversal. Following the announcement on March 9, the stock surged roughly 48.36% in a single week, with the latest session adding another strong gain.
Short interest and investor skepticism had previously increased amid regulatory concerns. Now that the legal dispute appears resolved, the market is reassessing the company’s long-term position in the rapidly expanding digital healthcare sector.
Progyny faces a very different analyst outlook
While Hims gained bullish attention, another healthcare company received a more cautious assessment from analysts. Canaccord lowered its price target on fertility benefits provider Progyny (NASDAQ: PGNY) to $19 from $26, maintaining a Hold rating.
Progyny reported $1.289 billion in full-year 2025 revenue, up 10.4% year over year, along with record adjusted EBITDA of $222.09 million. The company ended the year with $210.19 million in operating cash flow, $112.24 million in cash, and no debt.
However, guidance for 2026 disappointed investors. Management expects revenue growth of only 5.1% to 9%, signaling a sharp slowdown compared with the prior year. Shares have fallen roughly 30.26% year to date and were trading near $17.91, close to the company’s recent $16.75 52-week low.
Short interest in PGNY has also increased, rising about 41% to 4.02 million shares, reflecting growing investor caution despite the company’s debt-free balance sheet.
For now, Wall Street sentiment appears to be moving in opposite directions for the two healthcare stocks. While Progyny faces questions about slowing growth, Hims & Hers is gaining renewed attention as investors evaluate the scale of its opportunity in the rapidly expanding GLP-1 market.
You May Also Like
North London Derby: Why This Historic Rivalry Still Dominates Football Headlines
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
